Cargando…

MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer

BACKGROUND: Overtreatment of axillary lymph node dissection (ALND) may occur in patients with axillary positive sentinel lymph node (SLN) but negative non-SLN (NSLN). Developing a magnetic resonance imaging (MRI)-based radiomics nomogram to predict axillary NSLN metastasis in patients with SLN-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Ya, Zhang, Xiang, Wu, Zhiyuan, Wu, Shiji, Yang, Zehong, Wang, Dongye, Le, Hongbo, Mao, Jiaji, Dai, Guochao, Tian, Xuwei, Zhou, Renbing, Huang, Jiayi, Hu, Lanxin, Shen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920306/
https://www.ncbi.nlm.nih.gov/pubmed/35296027
http://dx.doi.org/10.3389/fonc.2022.811347
_version_ 1784669100324159488
author Qiu, Ya
Zhang, Xiang
Wu, Zhiyuan
Wu, Shiji
Yang, Zehong
Wang, Dongye
Le, Hongbo
Mao, Jiaji
Dai, Guochao
Tian, Xuwei
Zhou, Renbing
Huang, Jiayi
Hu, Lanxin
Shen, Jun
author_facet Qiu, Ya
Zhang, Xiang
Wu, Zhiyuan
Wu, Shiji
Yang, Zehong
Wang, Dongye
Le, Hongbo
Mao, Jiaji
Dai, Guochao
Tian, Xuwei
Zhou, Renbing
Huang, Jiayi
Hu, Lanxin
Shen, Jun
author_sort Qiu, Ya
collection PubMed
description BACKGROUND: Overtreatment of axillary lymph node dissection (ALND) may occur in patients with axillary positive sentinel lymph node (SLN) but negative non-SLN (NSLN). Developing a magnetic resonance imaging (MRI)-based radiomics nomogram to predict axillary NSLN metastasis in patients with SLN-positive breast cancer could effectively decrease the probability of overtreatment and optimize a personalized axillary surgical strategy. METHODS: This retrospective study included 285 patients with positive SLN breast cancer. Fifty five of them had metastatic NSLNs and 230 had non-metastatic NSLNs. MRI-based radiomic features of primary tumors were extracted and MRI morphologic findings of the primary tumor and axillary lymph nodes were assessed. Four models, namely, a radiomics signature, an MRI-clinical nomogram, and two MRI-clinical-radiomics nomograms were established based on MRI morphologic findings, clinicopathologic characteristics, and MRI-based radiomic features to predict the NSLN status. The optimal predictors in each model were selected using the 5-fold cross-validation (CV) method. Their predictive performances were determined by the receiver operating characteristic (ROC) curves analysis. The area under the curves (AUCs) of different models was compared by the Delong test. Their discrimination capability, calibration curve, and clinical usefulness were also assessed. RESULTS: The 5-fold CV analysis showed that the AUCs ranged from 0.770 to 0.847 for the radiomics signature, from 0.720 to 0.824 for the MRI-clinical nomogram, from 0.843 to 0.932 for the MRI-clinical-radiomics nomogram. The optimal predictive factors in the radiomics signature, MRI-clinical nomogram, and MRI-clinical-radiomics nomogram were one texture feature of diffusion-weighted imaging (DWI), two clinicopathologic features together with one MRI morphologic finding, and the DWI-based texture feature together with the two clinicopathologic features plus the one MRI morphologic finding, respectively. The MRI-clinical-radiomics nomogram with CA 15-3 included achieved the highest AUC compared with the radiomics signature (0.868 vs. 0.806, P <0.001) and MRI-clinical nomogram (0.868 vs. 0.761; P <0.001). In addition, the MRI-clinical-radiomics nomogram without CA 15-3 showed a higher performance than that of the radiomics signature (AUC, 0.852 vs. 0.806, P = 0.016) and the MRI-clinical nomogram (AUC, 0.852 vs. 0.761, P = 0.007). The MRI-clinical-radiomics nomograms showed good discrimination and good calibration. Decision curve analysis demonstrated that the MRI-clinical-radiomics nomograms were clinically useful. CONCLUSION: The MRI-clinical-radiomics nomograms developed in our study showed high predictive performance, which can be used to predict the axillary NSLN status in SLN-positive breast cancer patients before surgery.
format Online
Article
Text
id pubmed-8920306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89203062022-03-15 MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer Qiu, Ya Zhang, Xiang Wu, Zhiyuan Wu, Shiji Yang, Zehong Wang, Dongye Le, Hongbo Mao, Jiaji Dai, Guochao Tian, Xuwei Zhou, Renbing Huang, Jiayi Hu, Lanxin Shen, Jun Front Oncol Oncology BACKGROUND: Overtreatment of axillary lymph node dissection (ALND) may occur in patients with axillary positive sentinel lymph node (SLN) but negative non-SLN (NSLN). Developing a magnetic resonance imaging (MRI)-based radiomics nomogram to predict axillary NSLN metastasis in patients with SLN-positive breast cancer could effectively decrease the probability of overtreatment and optimize a personalized axillary surgical strategy. METHODS: This retrospective study included 285 patients with positive SLN breast cancer. Fifty five of them had metastatic NSLNs and 230 had non-metastatic NSLNs. MRI-based radiomic features of primary tumors were extracted and MRI morphologic findings of the primary tumor and axillary lymph nodes were assessed. Four models, namely, a radiomics signature, an MRI-clinical nomogram, and two MRI-clinical-radiomics nomograms were established based on MRI morphologic findings, clinicopathologic characteristics, and MRI-based radiomic features to predict the NSLN status. The optimal predictors in each model were selected using the 5-fold cross-validation (CV) method. Their predictive performances were determined by the receiver operating characteristic (ROC) curves analysis. The area under the curves (AUCs) of different models was compared by the Delong test. Their discrimination capability, calibration curve, and clinical usefulness were also assessed. RESULTS: The 5-fold CV analysis showed that the AUCs ranged from 0.770 to 0.847 for the radiomics signature, from 0.720 to 0.824 for the MRI-clinical nomogram, from 0.843 to 0.932 for the MRI-clinical-radiomics nomogram. The optimal predictive factors in the radiomics signature, MRI-clinical nomogram, and MRI-clinical-radiomics nomogram were one texture feature of diffusion-weighted imaging (DWI), two clinicopathologic features together with one MRI morphologic finding, and the DWI-based texture feature together with the two clinicopathologic features plus the one MRI morphologic finding, respectively. The MRI-clinical-radiomics nomogram with CA 15-3 included achieved the highest AUC compared with the radiomics signature (0.868 vs. 0.806, P <0.001) and MRI-clinical nomogram (0.868 vs. 0.761; P <0.001). In addition, the MRI-clinical-radiomics nomogram without CA 15-3 showed a higher performance than that of the radiomics signature (AUC, 0.852 vs. 0.806, P = 0.016) and the MRI-clinical nomogram (AUC, 0.852 vs. 0.761, P = 0.007). The MRI-clinical-radiomics nomograms showed good discrimination and good calibration. Decision curve analysis demonstrated that the MRI-clinical-radiomics nomograms were clinically useful. CONCLUSION: The MRI-clinical-radiomics nomograms developed in our study showed high predictive performance, which can be used to predict the axillary NSLN status in SLN-positive breast cancer patients before surgery. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8920306/ /pubmed/35296027 http://dx.doi.org/10.3389/fonc.2022.811347 Text en Copyright © 2022 Qiu, Zhang, Wu, Wu, Yang, Wang, Le, Mao, Dai, Tian, Zhou, Huang, Hu and Shen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qiu, Ya
Zhang, Xiang
Wu, Zhiyuan
Wu, Shiji
Yang, Zehong
Wang, Dongye
Le, Hongbo
Mao, Jiaji
Dai, Guochao
Tian, Xuwei
Zhou, Renbing
Huang, Jiayi
Hu, Lanxin
Shen, Jun
MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer
title MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer
title_full MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer
title_fullStr MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer
title_full_unstemmed MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer
title_short MRI-Based Radiomics Nomogram: Prediction of Axillary Non-Sentinel Lymph Node Metastasis in Patients With Sentinel Lymph Node-Positive Breast Cancer
title_sort mri-based radiomics nomogram: prediction of axillary non-sentinel lymph node metastasis in patients with sentinel lymph node-positive breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920306/
https://www.ncbi.nlm.nih.gov/pubmed/35296027
http://dx.doi.org/10.3389/fonc.2022.811347
work_keys_str_mv AT qiuya mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT zhangxiang mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT wuzhiyuan mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT wushiji mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT yangzehong mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT wangdongye mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT lehongbo mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT maojiaji mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT daiguochao mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT tianxuwei mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT zhourenbing mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT huangjiayi mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT hulanxin mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer
AT shenjun mribasedradiomicsnomogrampredictionofaxillarynonsentinellymphnodemetastasisinpatientswithsentinellymphnodepositivebreastcancer